The Binding Site GmbH

FreeliteTM use is now included in latest National Comprehensive Cancer Network (NCCN) guidelines

Birmingham, October 2010

The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 21 leading cancer centers in the USA is dedicated to improving the quality and effectiveness of care provided to patients with cancer.
The NCCN Clinical Practice Guidelines in Oncology recommend the use of serum free light chain assays (Freelite®) in the initial diagnostic workup of multiple myeloma and related disorders.
“Use of free light chain (FLC) assay along with SPEP and SIFE yields high sensitivity while screening for MM and related plasma cell disorders. Therefore, this assay is now included as a part of the initial diagnostic workup in the NCCN Multiple Myeloma Guidelines”.
Freelite assays are manufactured and sold by Binding Site to measure free kappa and free lambda immunoglobulin light chains in serum. The use of these quantitative, highly specific, automatable free light chain assays are also included in international guidelines for the diagnosis, prognosis and monitoring of multiple myeloma and Monoclonal Gammopathy of Undetermined Significance.
Paul Duncan, Group Sales and Marketing Director of the Binding Site said;
“These new guidelines reflect the considerable evidence for the role of Freelite in the diagnosis of Multiple Myeloma and its contribution to patient management.”
Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines™) for Multiple Myeloma V.1.2011. © 2010 National Comprehensive Cancer Network, Inc. All rights reserved.
For more information log onto www.nccn.org, www.bindingsite.com or talk to your local Binding Site representative.